Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase ™
Agenerase ™ demonstrates promising once-daily dosing results, allowing for simplified HIV therapy. The amprenavir prodrug, VX-175, offers significant simplification of protease inhibitor-based treatment by enabling daily dosing of just two or three pills.